Trial Profile
Phase II trial of sunitinib in bronchoalevolar carcinoma or never-smokers with any lung adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2010
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Bronchiolo-alveolar adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 05 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 05 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2009 Planned end date changed from 1 Dec 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.